Zhao Yi, Wang Qiang, Deng Xin, Shi Peng, Wang Zhen
Department of Gastroenterology Surgery, Affiliated Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, 110004, China.
Tumour Biol. 2013 Aug;34(4):2121-6. doi: 10.1007/s13277-013-0695-1. Epub 2013 Jun 14.
Glutathione S-transferase P1 (GSTP1) gene Ile105Val polymorphism has been suggested to be involved in the development of cancer. However, the results from the studies regarding the association between GSTP1 Ile105Val polymorphism and hepatocellular carcinoma risk have been inconsistent. Thus, we performed a meta-analysis to investigate the association. Published literature from PubMed, Chinese Biomedical Literature, and Wanfang databases was searched for eligible publications. Pooled odds ratios (ORs) with 95 % confidence intervals (95 %CIs) were calculated using random- or fixed-effects model. Six studies with a total of 1,843 participants were finally included into this meta-analysis. The results suggested there was no association between GSTP1 Ile105Val polymorphism and hepatocellular carcinoma risk under all genetic models (for ValVal vs. IleIle, OR = 0.79, 95 %CI 0.48-1.29, P = 0.341; for IleVal vs. IleIle, OR = 1.05, 95 %CI 0.84-1.30, P = 0.678; for the dominant model, OR = 0.91, 95 %CI 0.68-1.20, P = 0.498; and for the recessive model, OR = 0.76, 95 %CI 0.47-1.24, P = 0.269). Subgroup analyses by ethnicity showed there was also no association between GSTP1 Ile105Val polymorphism and hepatocellular carcinoma risk in Asians under all genetic models (All P values were more than 0.05), but GSTP1 Ile105Val polymorphism was associated with decreased risk of hepatocellular carcinoma in European under the recessive model (ValVal vs. IleVal/IleIle) (OR = 0.44, 95 %CI 0.20-0.98, P = 0.044). In conclusion, the meta-analysis suggests that there is little evidence for the association between GSTP1 Ile105Val polymorphism and hepatocellular carcinoma risk. However, more well-designed studies are needed to further assess this association.
谷胱甘肽S-转移酶P1（GSTP1）基因Ile105Val多态性被认为与癌症的发生有关。然而，关于GSTP1 Ile105Val多态性与肝细胞癌风险之间关联的研究结果并不一致。因此，我们进行了一项荟萃分析来研究这种关联。通过检索PubMed、中国生物医学文献数据库和万方数据库中的已发表文献来寻找符合条件的出版物。使用随机效应模型或固定效应模型计算合并比值比（OR）及其95%置信区间（95%CI）。最终，六项研究共1843名参与者被纳入该荟萃分析。结果表明，在所有遗传模型下，GSTP1 Ile105Val多态性与肝细胞癌风险之间均无关联（ValVal与IleIle相比，OR = 0.79，95%CI 0.48 - 1.29，P = 0.341；IleVal与IleIle相比，OR = 1.05，95%CI 0.84 - 1.30，P = 0.678；显性模型下，OR = 0.91，95%CI 0.68 - 1.20，P = 0.498；隐性模型下，OR = 0.76，95%CI 0.47 - 1.24，P = 0.269）。按种族进行的亚组分析表明，在所有遗传模型下，亚洲人中GSTP1 Ile105Val多态性与肝细胞癌风险之间也无关联（所有P值均大于0.05），但在隐性模型（ValVal与IleVal/IleIle相比）下，欧洲人中GSTP1 Ile105Val多态性与肝细胞癌风险降低相关（OR = 0.44，95%CI 0.20 - 0.98，P = 0.044）。总之，荟萃分析表明，几乎没有证据支持GSTP1 Ile105Val多态性与肝细胞癌风险之间存在关联。然而，需要更多设计良好的研究来进一步评估这种关联。
